Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

CagriSema peptide iconCagriSema37 residues (approx.)KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTPEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

CagriSema

Beginner tier: 0.25 mg, weekly · clinical trials

~7 days half-life·Injection

Also known as: CagriSema, cagrilintide-semaglutide, NNC9204-1706

REDEFINE 1 enrolled 3,417 adults and recorded 22.7% mean body weight loss over 68 weeks. CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist) in a single weekly pre-filled pen. It beat semaglutide alone by nearly seven percentage points. Fewer than two-thirds of trial participants reached the full 2.4/2.4 mg maintenance dose, though, and REDEFINE 4 (February 2026, n=809) showed tirzepatide producing 25.5% loss compared to CagriSema's 23.0%. The NDA was filed in December 2025. Adults with obesity seeking results beyond GLP-1 monotherapy are tracking the FDA decision expected around October 2026.

What Is CagriSema?

22.7% of body weight gone in 68 weeks. That number comes from REDEFINE 1 [1], a Phase 3 trial of 3,417 adults with obesity or overweight.

CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) is a fixed-dose combination in one pre-filled pen. Novo Nordisk developed it. Cagrilintide is a long-acting amylin analog. Semaglutide is the GLP-1 receptor agonist behind Ozempic and Wegovy. Each targets a separate appetite circuit in the brain; the combination produces additive suppression confirmed in head-to-head arms of the same trial.

Roughly 40% of participants on the full dose lost 25% or more of their body weight. Another 23% crossed the 30% threshold. In adults with type 2 diabetes, REDEFINE 2 [2] recorded 15.7% weight loss, and 73.5% of participants reached HbA1c at or below 6.5%.

Positioning got complicated in February 2026. REDEFINE 4 (n=809) tested CagriSema against tirzepatide 15 mg. CagriSema hit 23.0%; tirzepatide landed at 25.5%. The primary non-inferiority endpoint was missed. That head-to-head result shifted the conversation about where this drug fits.

The NDA was filed in December 2025. No PDUFA date has been made public, and CagriSema is not FDA-approved as of October 2026. Grey-market access means stacking separate research-grade cagrilintide and semaglutide vials, a fundamentally different product than the proprietary co-formulation tested in Phase 3.

How CagriSema Works

Two appetite pathways, one injection. That is the core idea behind CagriSema.

Cagrilintide is a synthetic analog of amylin, a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells. It activates amylin receptors (calcitonin receptor paired with receptor activity-modifying proteins, or RAMPs) in the area postrema and hypothalamus. Activation slows gastric emptying and sends early satiety signals that reduce meal size. A lipid side chain extends the half-life to approximately 184 hours.

Semaglutide activates GLP-1 receptors in the hypothalamus and brainstem nucleus tractus solitarius. Downstream effects include glucose-dependent insulin secretion, glucagon suppression, and central appetite reduction through incretin signaling. Its half-life runs about 158 hours.

These two receptor systems occupy different real estate in the brain. Amylin receptors signal primarily through the area postrema. GLP-1 receptors concentrate in the hypothalamus and nucleus tractus solitarius. REDEFINE 1 confirmed additive appetite suppression: 22.7% weight loss for the combination vs 16.1% for semaglutide alone and 11.5% for cagrilintide alone. Neither component matched the combination, confirming true pharmacological additivity.

Both components also slow gastric emptying. That overlap explains why GI adverse events hit 80% of REDEFINE 1 participants, the highest rate of any GLP-1 class drug.

CagriSema Benefits

  • CagriSema benefits center on dual-pathway weight loss and metabolic improvement backed by two large Phase 3 trials.
  • 22.7% mean body weight loss at 68 weeks in REDEFINE 1 (n=3,417)[1]. The treatment-policy estimand landed at 20.4%.
  • Roughly 40% of full-dose participants hit 25% or greater total weight loss. Another 23% crossed the 30% threshold, numbers that exceed any published semaglutide trial.
  • In patients with type 2 diabetes, 73.5% achieved HbA1c at or below 6.5% in REDEFINE 2 [2], with 15.7% body weight loss on top.
  • Systolic blood pressure dropped 10.9 mmHg in the AHA Hypertension 2025 sub-study [3]. Roughly 40% of participants on antihypertensives reduced or stopped their medications.
  • hsCRP fell 68.9% from baseline (ObesityWeek 2025 post-hoc), suggesting anti-inflammatory effects beyond what weight loss alone would explain.
  • One weekly injection covers both mechanisms. The pre-filled pen removes reconstitution, mixing, and double-injection burden.

CagriSema: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Strong
Based on 7 key studies·Phase 3

Phase 3 REDEFINE program confirms 22.7% body weight loss (efficacy estimand, REDEFINE 1) in obesity without T2D at 68 weeks.

Dosing studied: 0.25/0.25 mg each component weekly (start) → 2.4/2.4 mg weekly (maintenance); 16-week titration required
Read the evidence (key study, limitations)

REDEFINE 4 (Feb 2026) showed CagriSema at 23.0% weight loss failed non-inferiority vs tirzepatide at 25.5%. NDA filed December 2025. No PDUFA date has been made public.

Key Study

REDEFINE 1 (NEJM June 2025, PMID 40544433): n=3,417, 68-week Phase 3 RCT, CagriSema vs semaglutide alone vs cagrilintide alone vs placebo. REDEFINE 4 (Feb 2026, n=809): head-to-head vs tirzepatide 15 mg: CagriSema 23.0% vs tirzepatide 25.5%; primary endpoint (non-inferiority) not achieved.

Limitations

Not yet FDA-approved (NDA under review). Failed non-inferiority vs tirzepatide in REDEFINE 4. DEXA sub-study (n=252) showed 33% of weight lost was lean soft-tissue mass. Fewer than 2/3 of REDEFINE 1 participants reached full 2.4/2.4 mg maintenance dose by week 68. CVOT (REDEFINE 3, n=~7,000) ongoing: no cardiovascular outcomes data yet. 80% GI adverse event rate is the highest of any GLP-1 class drug.

Community Experience
Moderate
4.0/5
Based on ~200–400 Reddit threads (r/peptides, r/GLP1, r/Ozempic)

High interest driven by trial data.

Community dosing: Semaglutide 0.25 mg → 2.4 mg + cagrilintide 0.25 mg → 2.4 mg weekly, following REDEFINE schedule. Some community protocols titrate cagrilintide faster (0.6 → 2.4 mg) while semaglutide follows standard GLP-1 schedule.
Read the reports (what users report 4, common issues 6)

Actual grey-market access requires DIY stacking of separate research-grade cagrilintide + semaglutide. Users report strong appetite suppression but significant GI burden early in titration. REDEFINE 4 failure vs tirzepatide dampened enthusiasm in early 2026. Community consensus: do not initiate without prior GLP-1 experience.

What users report (4)
  • Additive appetite suppression ("food noise elimination") beyond semaglutide alone: community reports dramatically reduced hunger at maintenance
  • ~40% of trial participants achieved ≥25% weight loss: cited as primary motivator for community use
  • Once-weekly injection for the commercial formulation: maximally convenient vs daily peptides
  • Sustained weight loss with fewer plateaus than reported on semaglutide monotherapy
Common issues (6)
  • GI adverse events (~80% incidence): widely reported as significantly worse than semaglutide alone; dominant early complaint
  • Not FDA-approved; grey-market DIY stack (separate peptides) is NOT equivalent to the proprietary co-formulation; doubled injection burden
  • Lean mass loss (~33% of total weight lost per DEXA sub-study) requires active muscle preservation strategy
  • 16-week titration required before reaching maintenance: users who skip steps pay with severe GI events
  • REDEFINE 4 failure vs tirzepatide raised questions about positioning vs existing approved options
  • Cost of grey-market DIY stack: ~$400–700/month without insurance or approved product
Partially Aligned

Community follows REDEFINE titration schedule closely on dose escalation. Divergence: community uses separate research-grade cagrilintide + semaglutide (not the proprietary fixed-dose co-formulation validated in Phase 3). Some community protocols front-load cagrilintide titration faster than semaglutide. Both science and community agree the starting dose is 0.25 mg per component: community knows the correct initiation dose.

CagriSema Dosage Guide

Clinical TrialREDEFINE 1 Phase 3 Trial: cagrilintide + semaglutide (NEJM 2025)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner0.25 mgWeekly
Moderate1.7 mgWeekly
Aggressive2.4 mgWeekly
Note:

CagriSema comes as a pre-filled pen. No reconstitution, no BAC water, no vial math. Dial to the prescribed dose, inject, done. Store at 2 to 8 degrees Celsius; do not freeze.

For the grey-market DIY route (separate cagrilintide plus semaglutide vials), the reconstitution math matters. A 5 mg cagrilintide vial with 2 mL BAC water gives 2.5 mg/mL. For the 0.25 mg starting dose, draw 0.1 mL (10 IU on an insulin syringe). A 10 mg vial with 2 mL gives 5 mg/mL; the same 0.25 mg dose is 0.05 mL (5 IU). Run semaglutide math based on your vial concentration.

The 16-week titration is non-negotiable. Four weeks at each step: 0.25, 0.5, 1.0, 1.7, then 2.4 mg per component. Do not skip steps. Community users who rushed titration ended up with severe nausea and often quit entirely. If 1.7 mg is your ceiling, stay there; fewer than two-thirds of REDEFINE 1 participants made it to the full dose, and 1.7 mg still produces meaningful weight loss.

Cycling

No scheduled off period.

Based on 68-week REDEFINE Phase 3 trial design. Intended for long-term use. Weight regain expected upon discontinuation, consistent with GLP-1 agonist class. Titrate over 16 weeks before reaching maintenance dose.

Calculate your CagriSema dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

CagriSema Protocols by Goal

beginnerClinical Trial68 weeks (REDEFINE 1 trial); intended for long-term continuous use beyond 68 weeks
Titration step 1
Wk 1–4
0.25 mg cagrilintide + 0.25 mg semaglutide (0.5 mg total) · Weekly · Subcutaneous
Titration step 2
Wk 5–8
0.5 mg cagrilintide + 0.5 mg semaglutide (1.0 mg total) · Weekly · Subcutaneous
Titration step 3
Wk 9–12
1.0 mg cagrilintide + 1.0 mg semaglutide (2.0 mg total) · Weekly · Subcutaneous
Titration step 4
Wk 13–16
1.7 mg cagrilintide + 1.7 mg semaglutide (3.4 mg total) · Weekly · Subcutaneous
Maintenance
Wk 17+
2.4 mg cagrilintide + 2.4 mg semaglutide (4.8 mg total) · Weekly · Subcutaneous

Expected: 22.7% mean body weight loss at 68 weeks (efficacy estimand); 20.4% treatment-policy estimand. ~40% achieve ≥25% loss; ~23% achieve ≥30% loss. Systolic BP reduction ~10.9 mmHg (AHA Hypertension 2025 sub-study). hsCRP reduction ~68.9%.

Monitor: Weight monthly; HbA1c and fasting glucose quarterly (pre-diabetic patients); lipid panel baseline and 6 months; BP monthly during titration, quarterly at maintenance; amylase/lipase if abdominal pain; DEXA at baseline and 6 months recommended to track lean mass.

How to Inject CagriSema

  1. 1
    Pick a day of the week

    Same day every week. Any time of day, with or without food.

  2. 2
    Step 2

    For the pre-filled pen (commercial product, pending FDA approval): remove the cap, attach a pen needle (30 to 32 gauge, 4 to 8 mm), and dial to the prescribed dose. Clean the injection site with an alcohol swab. Inject subcutaneously into the abdomen (at least 2 inches from the navel), front of the thigh, or back of the upper arm. Hold for 10 seconds. Rotate sites weekly.

  3. 3
    Step 3

    For DIY research-grade stacking: reconstitute cagrilintide and semaglutide in separate vials. A 5 mg cagrilintide vial plus 2 mL BAC water gives 2.5 mg/mL. Doses by titration step: 0.25 mg equals 10 IU (0.1 mL); 0.5 mg equals 20 IU (0.2 mL); 1.0 mg equals 40 IU (0.4 mL); 1.7 mg equals 68 IU (0.68 mL); 2.4 mg equals 96 IU (0.96 mL).

  4. 4
    Step 4

    Draw each peptide into a separate insulin syringe (29 to 31 gauge). Do not combine them in one syringe. No validated stability data supports pre-blended mixtures outside Novo Nordisk's proprietary formulation.

  5. 5
    Inject each subcutaneously

    Pinch a skin fold, insert at 90 degrees, inject slowly, hold for 5 to 10 seconds, withdraw.

  6. 6
    Step 6

    Follow the 16-week titration: weeks 1 to 4 at 0.25/0.25 mg, weeks 5 to 8 at 0.5/0.5 mg, weeks 9 to 12 at 1.0/1.0 mg, weeks 13 to 16 at 1.7/1.7 mg, then 2.4/2.4 mg maintenance from week 17 onward.

  7. 7
    Store reconstituted vials at 2 to 8 degrees Celsius

    Use within 28 days. Do not freeze.

CagriSema Stacking Protocols

Works With

Avoid

Cagrilintide (standalone)

CagriSema already contains cagrilintide 2.4 mg at maintenance: additional cagrilintide creates amylin receptor over-stimulation and dramatically worsens GI adverse event risk.

Do not combine
Semaglutide (standalone)

CagriSema already contains semaglutide 2.4 mg: do not add additional semaglutide. Redundant GLP-1 agonism with additive GI risk and no meaningful additional efficacy.

Do not combine
Tirzepatide

Overlapping GLP-1 agonism (CagriSema contains semaglutide). Additive GI toxicity without additive weight loss benefit. REDEFINE 4 compared these head-to-head: they are alternatives, not complements.

Do not combine
Retatrutide

Triple receptor agonist with GLP-1 component: GLP-1 mechanism overlaps with semaglutide in CagriSema. Combined GI adverse event burden would be extreme. No evidence base for combination.

Do not combine
Liraglutide

GLP-1 agonist: redundant with semaglutide component of CagriSema. Do not combine any GLP-1 agonists.

Do not combine

Estimated Cost

Brand Price
Not yet commercially available (NDA filed December 2025; no public PDUFA date and not FDA-approved as of October 2026). Expected launch price ~$500–1,000/month by analogy with Zepbound/tirzepatide launch pricing. Subject to insurance coverage and Novo Nordisk patient assistance programs.
Generic / Research
Grey-market research-grade DIY stack only (separate cagrilintide + semaglutide; NOT equivalent to commercial CagriSema co-formulation). Combined cost ~$400–700/month depending on dose and product. Cagrilintide: ~$5.25/mg at 200 mg bulk up to ~$17.80/mg at 5 mg (research-grade pricing). Semaglutide: ~$3.92–4.98/mg (research-grade). Pre-blended combined vials also circulate but lack validated stability data.

Pricing updated 2026-04-09

CagriSema Side Effects

80% of REDEFINE 1 participants experienced gastrointestinal adverse events. That is the highest GI rate of any GLP-1 class drug in a Phase 3 trial. For comparison, semaglutide alone in STEP 1 hit roughly 44%. The additive amylin effect on gastric motility drives the difference.

Nausea affected 55% of participants. Constipation hit 31%. Vomiting was reported in 26%. Diarrhea was also common. Most events graded mild to moderate and concentrated in the first 16 weeks during dose titration. They tend to diminish as the body adapts to dual receptor activation. But "mild nausea" five days a week still disrupts daily life, and an 80% rate means the clear majority of users will face some degree of GI disturbance.

Constipation deserves separate attention because both components slow gut motility through independent mechanisms. Amylin delays gastric emptying from above; GLP-1 slows intestinal transit from below. The synergistic effect is predictable and was the most persistent GI complaint even after titration, based on community reports. Fiber, hydration, and osmotic laxatives (polyethylene glycol) are typically enough to manage it.

Lean mass loss is a less visible but important concern. The REDEFINE 1 DEXA sub-study (n=252) found that 33% of total weight lost was lean soft-tissue mass. At 22.7% total body weight loss, that is a large absolute quantity of muscle and bone mineral content. Resistance training three to four times weekly, protein intake at or above 1.2 g/kg body weight, and GH secretagogue stacking (CJC-1295 no DAC plus Ipamorelin) are the standard community countermeasures.

Fewer than two-thirds of trial participants reached the full 2.4/2.4 mg maintenance dose. GI tolerability was the barrier. Skipping titration steps makes outcomes worse. Community users who started at 0.5 mg (double the correct starting dose) reported universally more severe nausea lasting weeks longer than the standard protocol.

Pancreatitis is a GLP-1 class risk. Persistent abdominal pain with nausea needs urgent evaluation with amylase and lipase testing. Do not attribute abdominal pain to "normal GI side effects" without ruling out pancreatitis.

The medullary thyroid carcinoma (MTC) boxed warning applies through the semaglutide component, based on rodent thyroid C-cell tumor data. Anyone with a personal or family history of MTC or MEN2 should not use CagriSema. Baseline TSH testing is recommended with annual monitoring.

Rapid weight loss increases cholelithiasis (gallstone) risk. An abdominal ultrasound at baseline and six months is worth considering for anyone losing more than 1% body weight per week.

Discontinuation due to adverse events ran about 6% in REDEFINE 1. Injection site reactions can occur but are generally minor with the pen format.

Pregnancy and breastfeeding are contraindicated. No reproductive safety data exists for the combination.

Common Issues & Solutions

Severe nausea/vomiting in weeks 1–8: Do not escalate the dose. Hold at the current titration step for an additional 4 weeks until symptoms resolve. Anti-nausea medications (ondansetron) are used clinically but were not studied in REDEFINE. The 80% GI event rate in REDEFINE 1 is the highest of any GLP-1 class drug: it is expected, not a sign of intolerance requiring discontinuation in most cases.

Cannot reach 2.4/2.4 mg maintenance dose: Fewer than 2/3 of REDEFINE 1 participants achieved full maintenance. 1.7 mg per component is a clinically validated and effective long-term dose: do not force escalation beyond tolerance. Weight loss at 1.7 mg is still significant.

Lean mass loss concern: DEXA sub-study confirmed 33% of weight lost was lean soft-tissue mass. Mitigate with: resistance training 3–4x/week, protein ≥1.2 g/kg body weight, and consider adding a GHRH/GHRP stack (CJC-1295 no DAC + Ipamorelin). Monitor with DEXA at 6 months.

Constipation (31% of REDEFINE 1 participants): The additive effect of both amylin (slows gastric emptying) and GLP-1 (slows gut motility) is synergistic for constipation. Increase fiber, hydration, and consider osmotic laxatives (polyethylene glycol). This is expected and usually manageable without dose reduction.

Weight loss plateaus despite maintenance dose: Confirm adequate protein intake and caloric deficit. The treatment-policy estimand (20.4%) vs efficacy estimand (22.7%) difference reflects the real-world impact of adherence: consistent weekly dosing and dietary discipline are required. Check for drug interactions delaying oral medication absorption.

Ask AI about this page

Ask AI for a second opinion on CagriSema dosing and side effects

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • History of pancreatitis
  • Pregnancy or breastfeeding
  • Known hypersensitivity to cagrilintide, semaglutide, or any excipients
  • Severe gastrointestinal disease (e.g., gastroparesis)
  • End-stage renal disease (insufficient data)

Drug Interactions

  • Insulin and sulfonylureas: increased hypoglycemia risk; dose adjustment may be needed
  • Oral medications: absorption may be delayed due to slowed gastric emptying from both components
  • Levothyroxine: monitor thyroid levels; GLP-1 agonists may alter exposure
  • Warfarin: monitor INR more frequently during initiation and dose changes
  • Oral contraceptives: delayed absorption possible due to gastric emptying effects; no confirmed clinical interaction but caution is advised
  • CagriSema already contains cagrilintide 2.4 mg at maintenance: additional cagrilintide creates amylin receptor over-stimulation and dramatically worsens GI adverse event risk.
  • Triple receptor agonist with GLP-1 component: GLP-1 mechanism overlaps with semaglutide in CagriSema. Combined GI adverse event burden would be extreme. No evidence base for combination.
  • GLP-1 agonist: redundant with semaglutide component of CagriSema. Do not combine any GLP-1 agonists.

Product Quality

Recommended Monitoring

TestWhenTarget
Body weightWeekly during titration; monthly at maintenanceGradual 0.5–1.5% loss per week during active loss phase
HbA1cBaseline; every 3 months (especially T2D and pre-diabetic patients)<5.7% (normal); <7.0% (T2D clinical goal)
Fasting glucoseWeekly for first 4 weeks; monthly thereafter (more frequently if on insulin or sulfonylurea)70–100 mg/dL (normal); 80–130 mg/dL (T2D pre-meal per ADA)
Lipid panel (fasting)Baseline; 6 monthsLDL <100 mg/dL; Triglycerides <150 mg/dL
Blood pressureMonthly during titration; quarterly at maintenance<130/80 mmHg
Amylase and LipaseBaseline; immediately if abdominal pain developsNot listed
Liver enzymes (AST, ALT)Baseline; annuallyNot listed
DEXA body compositionBaseline; 6 months (optional but strongly recommended)Fat mass loss >70% of total weight lost
TSH (thyroid)Baseline; annually or if symptoms developNot listed
Abdominal ultrasoundBaseline; at 6 months if losing >1% BW/weekNot listed
Body weight

Primary efficacy marker. Loss >1.5% BW/week increases gallbladder (cholelithiasis) and lean mass risk.

HbA1c

CagriSema improves glycemic control significantly; concurrent diabetes medications often require dose reduction to prevent hypoglycemia.

Fasting glucose

Hypoglycemia risk in T2D patients: CagriSema reduces caloric intake rapidly while improving insulin sensitivity.

Lipid panel (fasting)

CagriSema improves lipids; documents cardiometabolic benefit and guides statin management.

Blood pressure

AHA Hypertension 2025 sub-study (PMID 41328546): CagriSema reduces systolic BP -10.9 mmHg vs -2.8 mmHg placebo. ~40% of patients on antihypertensives reduced or stopped medications. Monitor for over-correction.

Amylase and Lipase

Pancreatitis is a GLP-1 class risk; abdominal pain with nausea must be evaluated emergently.

Liver enzymes (AST, ALT)

Establishes reference; GLP-1 agonists improve MASLD; documents hepatic safety.

DEXA body composition

REDEFINE 1 DEXA sub-study (n=252) showed 33% of weight lost was lean soft-tissue mass: tracking allows timely intervention (protein, resistance training, GH secretagogues) before excessive lean mass loss.

TSH (thyroid)

GLP-1 class carries theoretical MTC risk (rodent data). CagriSema inherits this class warning from the semaglutide component.

Abdominal ultrasound

Cholelithiasis (gallstones) risk increases with rapid weight loss. Baseline establishes gallbladder status; follow-up if rapid weight loss trajectory.

CagriSema Before and After

Weeks 1-4
0.25 mg/0.25 mg

Initial titration phase. GI side effects (nausea, constipation) most common early. Mild appetite reduction may begin. Body adapts to dual amylin + GLP-1 activation.

Weeks 5-8
0.5 mg/0.5 mg

Appetite suppression becomes more noticeable. Early weight loss of 2-5% expected. Nausea typically starts to subside as the dose stabilizes.

Weeks 9-16
1.0-1.7 mg/1.0-1.7 mg

Continued titration with progressive appetite and hunger reduction. Steady weight loss accelerates. Blood glucose and insulin sensitivity improve in those with type 2 diabetes.

Weeks 17-68
2.4 mg/2.4 mg maintenance

Full therapeutic dose. REDEFINE 1 showed 22.7% mean weight loss by week 68 (treatment-policy: 20.4%). About 40% of patients reached ≥25% loss and 23% reached ≥30%. GI side effects largely resolved.

Week 68+

Long-term maintenance at reduced body weight. Continued metabolic and cardiometabolic benefits expected while on therapy. Weight regain likely if treatment is stopped.

What to Expect

Weeks 1 through 4 (0.25 mg/0.25 mg): The first month is about GI adaptation, not weight loss. Both amylin and GLP-1 receptors engage immediately, slowing gut motility from injection one. Expect less than 1% body weight change. Nausea and constipation are at their worst during this window. Community reports split: some users tolerate the starting dose well, while others report significant nausea from the first shot. Users who started at 0.5 mg (skipping this step) reported universally worse outcomes. Appetite reduction is noticeable but subtle.

Weeks 5 through 8 (0.5 mg/0.5 mg): Appetite suppression picks up. Early weight loss of 2 to 4% body weight is expected. Community users describe this phase as comparable to semaglutide 1.0 mg with an added fullness signal from the amylin component. "Food noise" begins fading. GI symptoms stabilize for most, though constipation often peaks during this window before improving. Fatigue is common.

Weeks 9 through 16 (1.0 to 1.7 mg per component): The most dramatic phase. Hunger drops to near-absent levels. Portion sizes shrink substantially. Weight loss accelerates and blood glucose improves in those with type 2 diabetes. Most GI adaptation is complete by week 12. Some users report fatigue from rapid caloric reduction and become focused on protein intake. Hair thinning (telogen effluvium, consistent with rapid weight loss and not drug-specific) starts in a subset of users.

Weeks 17 through 68 (2.4 mg/2.4 mg maintenance): Full therapeutic dose. REDEFINE 1 recorded 22.7% mean weight loss by week 68. Systolic blood pressure dropped 10.9 mmHg (AHA Hypertension 2025)[3]. hsCRP fell 68.9%. About 40% of participants reached 25% or greater weight loss. Plateaus are less common than on semaglutide alone, per community reports. The primary ongoing concerns are cost ($400 to $700 per month on the grey market), lean mass preservation, and gallbladder monitoring. REDEFINE 4 results in February 2026 prompted some community members to reconsider tirzepatide as an alternative.

Post-discontinuation: Weight returns. No CagriSema-specific post-treatment data exists. By analogy with semaglutide cessation trials (STEP 1 extension), roughly two-thirds of lost weight comes back within a year of stopping. Appetite returns within one to two weeks of the last injection. Community consensus: long-term or indefinite use is required to hold results. Some users explore tapering to the lowest effective maintenance dose (1.0 or 1.7 mg per component) to reduce cost.

Detailed Timeline: Science vs Community

Weeks 1–4 (0.25 mg/0.25 mg)
Science

Minimal weight loss (<1%). Highest frequency of GI events (nausea, constipation, decreased appetite onset). Both amylin and GLP-1 receptors begin to engage; GI motility slowing begins immediately.

Community

Variable GI tolerance: some users report significant nausea from the first injection; others tolerate well. Users who started at 0.5 mg (incorrect) universally report worse outcomes. Appetite reduction is noticeable but subtle at this dose.

Weeks 5–8 (0.5 mg/0.5 mg)
Science

Early weight loss 2–4% body weight. GI symptoms begin to attenuate as receptor adaptation occurs. Measurable satiety signal improvement.

Community

"Food noise" reduction begins. Community describes this as comparable to semaglutide 1.0 mg with added amylin satiety effect (fullness signals appear faster at meals). GI symptoms improving but still present for most.

Weeks 9–16 (1.0–1.7 mg/1.0–1.7 mg)
Science

Weight loss accelerates; most GI adaptation complete by week 12. HbA1c improvements evident in T2D patients by week 9–12. Appetite suppression becomes pronounced.

Community

Community describes this as the most dramatic phase: hunger near-absent, portion sizes reduce dramatically. Some report fatigue from rapid weight loss and elevated focus on protein intake. Hair thinning begins in some (telogen effluvium consistent with rapid weight loss, not drug-specific).

Weeks 17–68 (2.4 mg/2.4 mg maintenance)
Science

22.7% mean body weight loss by week 68 (efficacy estimand, REDEFINE 1). BP reduction -10.9 mmHg systolic (AHA Hypertension 2025, PMID 41328546). hsCRP reduction -68.9% (ObesityWeek 2025 post-hoc). ~40% achieve ≥25% weight loss.

Community

Strong satisfaction at full maintenance. Plateaus less pronounced than reported on semaglutide alone. Cost is primary ongoing concern (~$400–700/month grey-market). REDEFINE 4 results (Feb 2026) led some community members to reconsider tirzepatide instead.

Post-discontinuation
Science

Weight regain expected upon discontinuation: no post-treatment extension data specific to CagriSema yet. By analogy with semaglutide cessation trials (STEP 1 extension): ~2/3 of lost weight regained within 1 year of stopping.

Community

Community universally accepts long-term or indefinite use is required to maintain results. Some explore dose reduction to lowest effective dose at goal weight to manage cost. Appetite returns within 1–2 weeks of stopping.

Pharmacokinetics

Half-Life
168h
Bioavailability
SC: estimated ~65% (cagrilintide); ~89% (semaglutide)
Tmax
Cagrilintide: 24-72h; Semaglutide: 12-24h
Data Confidence
moderate

Source: Phase 1b trial (Enebo et al., Lancet 2021, PMID 33894838): semaglutide t½ 145-165h, cagrilintide t½ 159-195h

Pharmacokinetics: Active Dose Over Time

t½ = ~7 days (semaglutide component ~158h; cagrilintide component ~184h)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
37
Sequence
KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: N/A (fixed-dose combination; individual CAS: cagrilintide 1415456-99-3, semaglutide 910463-68-2)

Who Should Consider CagriSema

  • Adults with BMI ≥30 (obesity)
  • Adults with BMI ≥27 with at least one weight-related comorbidity
  • Adults with obesity or overweight and type 2 diabetes
  • Patients who have plateaued on GLP-1 monotherapy
  • Individuals seeking greater weight loss than single-agent options

Related Peptides

What Changed for CagriSema

  1. Evidence

    Corrected Oct 7, 2026: CagriSema's investigational status now cites an active Phase 3 trial (REDEFINE 3), not a withdrawn one, per ClinicalTrials.gov.

    Before: Status source: ClinicalTrials.gov NCT07357766 only (a formulation trial withdrawn before enrolling) After: Status sources: ClinicalTrials.gov NCT05669755 (REDEFINE 3, Phase 3, active, not recruiting) and NCT07357766

    Source: ClinicalTrials.gov NCT05669755, REDEFINE 3 (CagriSema cardiovascular outcomes, Phase 3, active, not recruiting; last update posted Aug 31, 2026) (opens in a new tab) · Saved copy

  2. Evidence

    Two Novo Nordisk CagriSema formulation trials (NCT07357740, NCT07357766) were withdrawn before enrolling anyone, posted Jul 9, 2026, per ClinicalTrials.gov.

    What this does not mean: Both records say "withdrawn due to strategic reasons" with zero enrolled. It is not a safety or efficacy signal.

    Source: ClinicalTrials.gov NCT07357766 (and NCT07357740), CagriSema versions compared (opens in a new tab) · Saved copy

Dates to watch

  1. Trial primary completion, estimated

    REDEFINE 3, the Phase 3 heart outcomes trial of CagriSema, has an estimated primary completion date, per ClinicalTrials.gov.

    What this does not mean: Primary completion is when the last participant gives data for the main outcome, not when results come out. Estimated dates often move.

Peptide Schedule Research TeamReviewed Apr 7, 20267 Citations

References

  1. [1]REDEFINE 1: Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (NEJM 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]REDEFINE 2: Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (NEJM 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 (Hypertension 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
N/A: supplied as pre-filled injection pen
After Reconstitution
N/A: no reconstitution required
Temperature
2-8°C (36-46°F); do not freeze

Frequently Asked Questions

Frequency matters for adherence. Even mild nausea experienced by 80% of patients means the majority face meaningful quality-of-life disruption early in treatment; compared to semaglutide's 44% GI rate in STEP-1. The additive amylin effect on gastric motility drives this. Skipping titration steps is particularly dangerous for GI tolerability.

They act through completely separate receptor systems and brain circuits. GLP-1 receptors concentrate in the hypothalamus and brainstem nucleus tractus solitarius; amylin receptors signal primarily via the area postrema. REDEFINE 1 confirmed additive appetite suppression: 22.7% for the combination vs. 16.1% for semaglutide alone.

In REDEFINE 1, fewer than two-thirds of participants reached the full 2.4/2.4 mg dose by week 68. Novo Nordisk is designing REDEFINE 11 with modified escalation strategies to improve this. Patients staying at 1.7 mg or lower still lose significant weight but may not achieve the trial-reported 22.7%.

Novo Nordisk filed the NDA in December 2025 and said FDA was expected to review it in 2026. No PDUFA date has been made public, and CagriSema is not FDA-approved as of October 2026.

Technically possible, but the REDEFINE trials used a proprietary fixed-dose co-formulation with specific pH and excipients. Separate reconstitution doubles injection burden and introduces compatibility uncertainty; community protocols combining separate peptides are not validated against the Phase 3 formulation.